drugset / Trial / NCT02199743
Lurasidone Effects on Tissue Glutamate in Schizophrenia
Phase 4
Completed
35 enrolled
University of Texas Southwestern Medical Center
Sumitomo Pharma America, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
24 individuals with schizophrenia or schizoaffective disorders, who are currently considered stable, will be recruited, screened for entry criteria into a blinded study with a 4-week randomization to either lurasidone, haloperidol, or perphenazine to examine glutamate-related outcomes with lurasidone as compared to haloperidol and perphenazine.
Timeline
- Start
- 2013-02
- Primary completion
- 2016-06
- Completion
- 2016-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Haloperidol | Other / unclassified | 8 mg | Oral |
| Comparator | Lurasidone | Small molecule | 80 mg | Oral |
| Comparator | Perphenazine | Small molecule | 32 mg | Oral |